-+ 0.00%
-+ 0.00%
-+ 0.00%

Centessa Pharmaceuticals Announces Poster Presentation Of Phase 1 Clinical Data For ORX750, A Novel Orexin Receptor 2 Agonist, At The AAN 2025 Annual Meeting

Benzinga·03/06/2025 21:24:35
Listen to the news

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.

Details of the poster presentation are as follows:

Title: Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants

Abstract Number: 2277

Presenter: Deborah Hartman, PhD, Global Scientific Head, Orexin Program

Session Date and Time: Saturday, April 5, 2025, at 11:45 AM- 12:45 PM PT

Centessa's booth number is 627. AAN abstracts are available on the conference website. Centessa's poster will be available on the Centessa website at https://investors.centessa.com/events-presentations after the poster presentation concludes.